Clinical trials: Schizophrenia Spectrum, active
Schizophrenia
Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia
The investigators will test the hypothesis that auditory stimulation (playing quiet sounds during sleep) can normalize brain activity during sleep and improve memory in patients with schizophrenia.
- Trial name
- NCT04783571
- Testing
- Auditory Stimulation
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Anti-Inflammatory Challenge in Schizophrenia
This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain…
- Trial name
- NCT05823532
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Schizophrenia Disorders, Major Depression
Non-Coding RNAs Gene Expression in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major…
- Conditions
- Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- PsiRNA26 (NCT07649993)
- Testing
- Reverse Transcription Quantitative Polymerase Chain Reaction
- Where
- 5 sites in Italy
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Carmen Concerto
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Schizophrenia and Related Disorders, Major Depressive Disorder
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros.
- Conditions
- Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
- Trial name
- INTENSIFY (NCT05603104)
- Testing
- Clozapine, Esketamine Nasal Product, Escitalopram
- Where
- Israel
- Volunteers
- 1,254 people
- Sponsor
- Dr. Inge Winter
Psychosis
A Combined Aerobic and Resistance Training Program for Adults With Psychotic Disorders
The study is a feasibility study of a combined high intensity aerobic and strenght exercise program for persons with psychotic disorders.
- Trial name
- TREPP (NCT05719116)
- Testing
- Physical exercise
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Solli Distriktspsykiatriske Senter
Psychosis, Cannabis Use
Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis
Canada reports some of the highest rates of cannabis use in our youth and young adult populations, among all the developed countries.
- Trial name
- NCT07001878
- Testing
- Metformin
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Schizophrenia
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
The study aims to address the following questions: 1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes? 2.
- Trial name
- NCT07616999
- Where
- China
- Volunteers
- 178 people
- Sponsor
- The University of Hong Kong
Schizophrenia, Schizo Affective Disorder
Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia
This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study how hallucinations work in schizophrenia.
- Trial name
- NCT05343598
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Mclean Hospital
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Clinical High Risk for Psychosis (CHR)
Efficacy of Mindfulness in PREventing Progression to Psychosis in Individuals With an Ultra High Risk for Psychosis
The main objective is to evaluate the efficacy of a group-based mindfulness therapy programme in reducing distress associated with symptoms of UHR (Ultra High Risk) or FEP (first psychotic episode) compared with usual treatment.
- Trial name
- EM-PREPS (NCT06870305)
- Testing
- MBTP : Mindflulness based training for psychosis
- Where
- 2 sites in France
- Volunteers
- 270 people
- Sponsor
- Centre Psychothérapique de Nancy
Paranoia, Psychotic Disorders
Racial Disparities in the Expression of Paranoia
Paranoia is a pattern of thinking in which people feel suspicious or believe others may want to harm them. It can occur in many people, not only those with a mental health diagnosis, and it can affect daily life, relationships…
- Trial name
- NCT07460453
- Testing
- Guided Visual Imagery Task
- Where
- United States
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia / Schizoaffective Disorder, Depression / Major Depressive Disorder
Brain Imaging of Cognition Inn Schizophrenia and Depression
Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining…
- Trial name
- NCT04159662
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia, Schizoaffective Disorder
Integrative Neuro-social Cognitive Strategy Programme for Instilling REcovery (INSPIRE) a Community-Based Cognitive Remediation Trial
Adults with serious mental illnesses (such as schizophrenia and schizoaffective disorders) often experience a range of cognitive difficulties (such as memory, problem solving difficulties) that affect their ability to lead…
- Trial name
- NCT06286202
- Testing
- Cognitive Remediation: Adapted Neuropsychological and Education Approach to Remediation (NEAR), Standard Psychiatric Rehabilitation at Anglican Care Centers
- Where
- 5 sites in Singapore
- Volunteers
- 160 people
- Sponsor
- Singapore Institute of Technology
Apathy, Schizophrenia
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician …
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Trial name
- NCT06482554
- Testing
- Lumateperone 42 mg, Risperidone 2 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Schizophrenia / Schizoaffective Disorder
Healing Stigma Through Stories
This study is the first phase of the research project. The purpose of this phase is to develop and refine a narrative-based intervention designed to reduce self-stigma among people with schizophrenia.
- Trial name
- NCT07708402
- Testing
- Healing Stigma through Stories
- Volunteers
- 24 people
- Sponsor
- National Yang Ming Chiao Tung University
Schizophrenia
Tolerability of MDMA in Schizophrenia
Impaired social motivation, or "asociality," is a negative symptom of schizophrenia (SCZ) and a cause of significant functional impairment in the illness.
- Trial name
- TMS (NCT05770375)
- Testing
- MDMA 40mg, MDMA 80mg, MDMA 120mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Anya Bershad, MD, PhD
Psychosis, Alcohol Use Disorder
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in…
- Conditions
- Psychosis, Alcohol Use Disorder, Cannabis Use Disorder
- Trial name
- NCT07056894
- Testing
- Action-Based Cognitive Remediation
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Nova Scotia Health Authority
Clinical High Risk, Psychosis
AMP SCZ® Observational Study: PREDICT-DPACC
The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that…
- Conditions
- Clinical High Risk, Psychosis, Remission, Conversion
- Trial name
- AMP SCZ (NCT05905003)
- Where
- 42 sites in United States, Australia and 12 more
- Volunteers
- 2,617 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital